Incentives to Repurpose Existing Drugs for Orphan Indications

9Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The Orphan Drug Act has been successful in providing incentives to find cures for orphan diseases. However, many orphan diseases are still without cure. Therefore, the 114th Congress has introduced the 21st Century Cures Act and the Orphan Product Extension Now Accelerating Cures and Treatment Act of 2015 to further provide incentives to innovators to repurpose existing drugs for treatment of these orphan diseases. However, these bills are currently pending and their incentives might not go far enough.

Cite

CITATION STYLE

APA

Kwok, A. K., & Koenigbauer, F. M. (2015). Incentives to Repurpose Existing Drugs for Orphan Indications. ACS Medicinal Chemistry Letters, 6(8), 828–830. https://doi.org/10.1021/acsmedchemlett.5b00276

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free